Biodefense and special pathogen vaccines in development 2

Published on May 28, 2015   33 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

We will now walk through three case studies of biodefense vaccines. The first one will take us through over 300 years of medical history with the advent of variolation to prevent smallpox. The second study deals with the use of the FDA animal rule to expand the indication of BioThrax, the anthrax vaccine, from pre-exposure to post-exposure prophylaxis. And lastly, we will cover a more recent event that has mobilized the biomedical community in ways that we've never witnessed before, the Ebola outbreak.
Let's begin with smallpox. Smallpox is believed to have killed more people than all wars combined. It has devastated mankind for centuries. We are, indeed, fortunate for the work of Edward Jenner and the many scientists and clinicians that worked towards the ultimate eradication of this scourge from humanity. Along with rinderpest, a disease of ruminants, smallpox is the only other disease eradicated from this planet.

Biodefense and special pathogen vaccines in development 2

Embed in course/own notes